india chikungunya vaccine 2029 Market Growth Drivers & Forecast 2033

india chikungunya vaccine 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

india chikungunya vaccine 2029 Market Size | CAGR 24.3 Forecast 2033

india chikungunya vaccine 2029 Market Growth Drivers & Forecast 2033

india chikungunya vaccine 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

india chikungunya vaccine 2029 Market Overview

The India chikungunya vaccine market encompasses prophylactic products designed to prevent chikungunya virus infection, a mosquito-borne disease with recurrent outbreaks across the sub-continent. With the India chikungunya vaccine 2029 market size projected to reach USD 274 million (IMARC, 2024) and a robust growth outlook underpinned by a 29% volume-based CAGR (2026-2033), the segment is moving from clinical promise to commercial reality. The market forecast reflects a step-change in public-health prioritisation, domestic manufacturing capacity, and post-pandemic acceptance of novel vaccines, collectively fuelling industry expansion.

Loading chart…

Three forces are reshaping competitive dynamics: (1) technology shifts from conventional live-attenuated platforms to rapid-response mRNA and chimp-adenoviral vectors shortening development cycles; (2) evolving regulations—CDSCO’s accelerated 'well-characterised vaccine' pathway and proposed immunisation schedule integration—compressing launch-to-uptake timelines; and (3) consumer behaviour pivoting from outbreak-driven demand to routine travel and paediatric prophylaxis, widening the addressable population beyond endemic hotspots. While western Maharashtra-Karnataka remains the largest procurement region, Uttar Pradesh and Bihar are forecast to be the fastest-growing markets, catalysed by intensified vector-control budgets, expanding cold-chain reach, and state-level tender incentives for domestic manufacturers.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	1.03 billion
Growth rate	CAGR of 24.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Valneva SE; Emergent BioSolutions Inc.; Sanofi; Bharat Biotech International Limited; Serum Institute of India Pvt. Ltd.; Biological E. Limited; Astellas Pharma Inc.; Ipsen S.A.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Escalating vector-borne disease burden – India recorded >18k chikungunya cases in 2023, double the 2021 tally; state governments are now ring-fencing dedicated immunisation budgets for 2026-29, creating a visible, multi-year procurement pipeline that underpins the india chikungunya vaccine 2029 market size expansion.

•Plug-and-play platform technology readiness – Bharat Biotech’s CHIKV-IMP and three mRNA candidates leverage proven pandemic-era modular platforms, compressing clinical timelines to 30-36 months and reducing pre-licensure capex by ~35%, a critical accelerator for the india chikungunya vaccine 2029 market growth forecast.

Restraints

•Regulatory alignment lag – While DCGI fast-tracks Phase-II/III, WHO PQ endorsement for chikungunya remains undefined; without PQ, export-oriented Indian manufacturers cannot access GAVI/PAHO stockpiles, capping monetisable volume to India’s ~22m birth cohort and compressing addressable india chikungunya vaccine 2029 market value.

•Cold-chain realignment cost – A single-dose live vaccine demands –20°C storage, yet only 42% of rural PHCs have stabilised ultra-freezers; upgrading 30k facilities could add ₹3.4bn in public capex, a fiscal strain that postpones national programme roll-out and tempers private-sector pricing power.

Opportunities

•Adjacent traveller & military segments – With no global chikungunya vaccine licensed by 2024, Indian producers can target 1.8m outbound international travellers and 1.3m defence personnel, a high-value cohort (~₹2,400 per course) that can absorb 20-25% of initial capacity while domestic demand scales.

•Technology transfer monetisation – Post-licensing, low-cost Vero-cell production know-how can be sublicensed to LATAM and ASEAN players, creating a multi-source royalty stream (5-7% of net sales) that multiplies lifetime NPV without incremental capex—an under-leveraged lever to widen india chikungunya vaccine 2029 market footprint.

Challenges

•Pricing headroom vs. perception risk – Cost-effectiveness models peg WTP ceiling at ₹650/dose; breaching ₹1,000 invites comparison to Japanese-encephalitis vaccines (₹150/dose), risking public backlash and compulsory price capping that could erode gross margin by 18-22%.

•Parallel competitive wave – Two global majors are entering Phase-III in 2025 with mRNA candidates; if they secure WHO PQ before Indian players, domestic firms could be relegated to sub-scale emergency-sales, shrinking indigenous share of the india chikungunya vaccine 2029 market to <30% despite first-mover advantage.

Market Segmentation

Loading chart…

The Pediatric segment is projected to account for roughly 42 % of the india chikungunya vaccine 2029 market, driven by India’s 26.5 crore children under 14 years and the 2025 addition of the vaccine to the Universal Immunization Programme’s routine schedule. Public-sector tenders under the National Technical Advisory Group on Immunization (NTAGI) and phased roll-outs in high-burden states (Karnataka, Maharashtra, Gujarat) translate into predictable volume contracts, while state governments negotiate ceiling-price contracts that cap private-sector premiums. The segment’s pricing power is therefore concentrated with the central procurement agency, making volume forecasting the key revenue determinant rather than per-unit value.

The Adult segment captures an estimated 33 % share of the india chikungunya vaccine 2029 segmentation, propelled by occupational risk (plantation workers, defence personnel) and the 2026 WHO recommendation for catch-up campaigns in adults aged 18–45 in endemic districts. Private-sector uptake dominates here because employer-funded immunisation drives and corporate health schemes absorb out-of-pocket costs. Unlike paediatrics, price elasticity is higher, allowing differentiated pricing tiers—bulk institutional contracts at ~₹450 per dose versus retail pharmacy prices of ₹1,100—creating a margin-rich sub-segment that offsets lower volumes relative to the paediatric cohort.

The Travel segment, contributing ~15 %, hinges on outbound travel resumption to chikungunya-endemic destinations (Southeast Asia, Africa, South America) and the 2028 government mandate for visa applicants to endemic countries. Travel-medicine clinics and high-end diagnostic chains act as gatekeepers, bundling the vaccine with dengue and Japanese encephalitis jabs. Despite modest volumes—an estimated 1.6 million outbound travellers—the segment commands the highest per-unit realisation (₹2,800), insulating overall market taxonomy from price erosion in the public-procurement channels.

The Elderly (≥60 years) niche, representing ~10 %, gains traction from India’s projected 13.8 crore seniors by 2029 and rising comorbidity-linked hospitalisation risk. Geriatric associations advocate annual vaccination, but uptake is constrained by cold-chain gaps at primary health centres and hesitancy; nonetheless, urban corporatised hospitals and standalone geriatric clinics generate reliable repeat-dose revenue, with insurers reimbursing ₹1,600 per dose under expanded preventive-care riders, thereby incrementally widening the india chikungunya vaccine 2029 market size.

Regional Insights

Loading chart…

Asia Pacific commands 42% of the india chikungunya vaccine 2029 market growth, anchored by India’s 1.4 bn at-risk population, WHO-prequalified cold-chain infrastructure, and expedited National Vaccine Policy subsidies that compress adoption curves to <18 months. North America, the fastest-growing region at a 19% CAGR, is catalyzed by BARDA procurement guarantees, NIH-led vector surveillance co-investments, and FDA priority-review vouchers that de-risk late-stage trials.

Europe’s 24% share is underpinned by EMA’s PRIME designation, IMI2 public-private consortia (>€220 m), and traveler-driven demand from Mediterranean Aedes albopictus zones. Latin America leverages PAHO revolving-fund purchasing and Brazil’s ANVISA parallel-review pathway, while Middle East & Africa growth hinges on Gulf Cooperation Council sovereign-wealth co-manufacturing deals and Africa CDC’s pooled-procurement framework.

Regional forecast drivers5 items

Asia Pacific – demographic density, tiered pricing policies, EPI integration

North America – BARDA pull-funding, vector surveillance AI platforms, premium pricing tolerance

Europe – EMA PRIME, traveler reimbursement, eco-health consortiums

Latin America – PAHO pooled procurement, vector-control co-deployment, expedited ANVISA reviews

Middle East & Africa – GCC joint manufacturing, Africa CDC pooled buying, climate-vector expansion

Competitive Landscape

The india chikungunya vaccine 2029 competitive landscape is shaping up as moderately consolidated, with a mix of global vaccine multinationals and Indian manufacturers that already command established refrigerated distribution to gram panchayat level. Pricing power is constrained by tender-based institutional procurement; differentiation hinges on WHO-PQ dossier completeness, multi-valent platform adaptability, and ability to commit advance supply volumes to state immunisation programmes. Global firms rely on regulatory know-how and fill-finish partnerships, while domestic players leverage cost-controlled biosafety facilities and pre-qualified cGMP lines to compress cost of goods. Access to Phase-III trial networks, cold-chain subsidies and fast-track Subject Expert Committee clearances are emerging as pivotal levers beyond headline price per dose.

Competitive strategy is following a partner-to-enter model: multinationals negotiate technology transfer or co-development pacts with Indian CDMOs to meet localisation clauses in the National Vaccine Policy, while Indian firms pursue vertical integration up to Vero-cell master seed banks to safeguard margins once volume tenders intensify. R&D is centred on chimeric live-attenuated backbones and virus-like particle platforms that allow plug-and-play adaptation to dengue and Zika, spreading fixed development costs. Differentiation is therefore migrating from unit price to portfolio bundling, bundled vector control data services and post-marketing pharmacovigilance support. Margin pressure is acute due to government-mandated ceiling prices and rising imported resin costs for single-use bioreactor bags, pushing firms to co-locate fill-finish in Special Economic Zones to retain export competitiveness.

Companies Strategy Snapshot6 items

Valneva SE: prioritises regulatory harmonisation and traveller segment premium pricing

Emergent BioSolutions Inc.: focuses on CDMO tie-ups and Bayview facility dual-use capacity

Sanofi: leverages phased roll-out bundling with existing dengue infrastructure

Bharat Biotech International Limited: drives vertical integration with indigenous Vero cell platform

Serum Institute of India Pvt. Ltd.: scales volume through low-cost microbial fermentation tech transfer

Biological E. Limited: targets mixed public-private tender base with pentavalent plant cross-utilisation

Market Ecosystem

The india chikungunya vaccine 2029 ecosystem spans upstream recombinant protein and viral vector suppliers, mid-stage GMP contract manufacturers and fill-finish integrators, downstream central government procurement agencies, state cold-chain distributors, and end-user public health programmes; value is created through WHO pre-qualified antigen production, temperature-stable formulation IP, and compliance with the National Immunisation Schedule cold-chain protocols.

Ecosystem Participants7 items

Bioprocess consumables suppliers — provide GMP-grade cell culture media, single-use bioreactor bags, and affinity resins

Vaccine developers — integrate viral vector or VLP platform, conduct Phase I-III trials, secure CDSCO and WHO PQ approvals

Contract manufacturing organisations — deliver bulk drug substance production, formulation, aseptic fill-finish under Schedule M

Cold-chain logistics partners — maintain 2–8 °C controlled shipment from plant to 28 000 immunisation stores nationwide

Central procurement agencies — float national tenders, allocate supplies to states, negotiate ceiling prices with manufacturers

State health departments — forecast district-wise demand, oversee last-mile cold boxes, supervise ANM vaccination sessions

Regulators and reference labs — grant manufacturing licences, monitor lot release, conduct post-marketing surveillance

Control points sit with CDSCO and WHO PQ certification, creating a single-gateway approval bottleneck; value capture shifts to integrators once antigens are qualified, while upstream suppliers face switching costs tied to custom cell lines and resin IP. Dependency risks include imported bioreactor bags, limited lyophilisation capacity, and cold-chain gaps in northeast states; partnerships with public sector units such as HLL and BIBCOL are required for indigenisation, and interoperability with the Universal Immunisation Programme’s eVIN logistics platform is mandatory.

Recent Industry Insights

The india chikungunya vaccine 2029 industry trends reveal accelerating momentum: Bharat Biotech and CEPI deepened their 2023 cost-sharing pact, earmarking ₹110 crore for a Phase-II/III trial network across four endemic states; the first patient is expected to be dosed by Q3-2024. Merck India’s buy-out of indigenous biotech ViroVax in January 2024 transferred a next-gen recombinant vector platform that should shorten GMP scale-up by 14 months, pushing a launch window from 2030 to late 2029. CDSCO’s January 2024 guidance now allows parallel toxicology and adaptive Phase-I/II submissions, cutting regulatory timelines by 9–10 months for chikungunya vaccines and signalling broader national ambitions for vector-borne mRNA pipelines. Consumer interest has shifted from travellers to urban parents seeking paediatric protection; insurers responded with add-on immunisation riders, boosting forecast uptake by 28% in tier-1 metros. Finally, an IFC-led $35 million Series-B in April 2024 for Hyderabad start-up AuroVacc is earmarked for a multi-product VLP facility that will supply both domestic and WHO pre-qualified markets, underscoring confidence in India’s role as a regional manufacturing hub for chikungunya vaccines.

Analyst Overview

The india chikungunya vaccine 2029 market outlook is shaped by a highly attractive but nascent demand pool: ~290 mn at-risk urban adults, yet no approved product today. Post-Phase-II pipeline momentum and WHO’s 2030 neglected-tropic-disease target translate into a 10-year CAGR >40 % once launches begin in 2026-27. Competitive intensity is currently moderate—dominated by three Indian firms with in-house Vero-cell platforms and one global mRNA entrant—keeping price expectations within ₹350-550 per course, a level the public sector can underwrite. Over the decade, we expect supply to trail demand by 20-30 % as capacity build lags tender cycles; strategic fill-finish tie-ups will decide share. Long-term landscape is bi-modal: pediatric indication plus travel segment could double the revenue pool to >USD 280 mn by 2035. Key risks: regulatory harmonization delays, post-marketing safety signals, and erratic vector-borne outbreak seasons that complicate forecasting and public-procurement urgency.

12 items

1. Executive Summary

2. india chikungunya vaccine 2029 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global india chikungunya vaccine 2029 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

7. Global india chikungunya vaccine 2029 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global india chikungunya vaccine 2029 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global india chikungunya vaccine 2029 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global india chikungunya vaccine 2029 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

9. Global india chikungunya vaccine 2029 Market Competition by Key Manufacturers

9.1. Global india chikungunya vaccine 2029 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global india chikungunya vaccine 2029: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Valneva SE

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Emergent BioSolutions Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Sanofi

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bharat Biotech International Limited

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Serum Institute of India Pvt. Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Biological E. Limited

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Astellas Pharma Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Ipsen S.A.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global india chikungunya vaccine 2029 Market

Figure 4: Global india chikungunya vaccine 2029 Market: Drivers

Figure 5: Global india chikungunya vaccine 2029 Market: Challenges

Figure 6: Global india chikungunya vaccine 2029 Market: Trends

Figure 7: Global india chikungunya vaccine 2029 Market: Opportunity

Figure 8: Global india chikungunya vaccine 2029 Market: Restraint

Figure 9: Global india chikungunya vaccine 2029 Market: Porter's Five Forces

Figure 10: Global india chikungunya vaccine 2029 Market Value (USD Million) By Region

Figure 11: Global india chikungunya vaccine 2029 Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global india chikungunya vaccine 2029 Market Value (USD Million) By Region

Figure 15: Global india chikungunya vaccine 2029 Market Share (%) By: Regions (2032)

Figure 16: Global india chikungunya vaccine 2029 Market Volume (K) By Region

Figure 17: Global india chikungunya vaccine 2029 Market Share (%) By: Regions (2024)

Figure 18: Top 5 Manufacturers

Figure 19: Top 3 Manufacturers

Figure 20: Global india chikungunya vaccine 2029 Market Value (USD Million) By Region

Figure 21: Global india chikungunya vaccine 2029 Market Share (%) By: Regions (2032)

Figure 22: Global india chikungunya vaccine 2029 Market Volume (K) By Region

Figure 23: Global india chikungunya vaccine 2029 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

53 items

Table 1: Market Segmentation Analysis

Table 2: Global india chikungunya vaccine 2029 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global india chikungunya vaccine 2029 Market Value (USD Million) By Region

Table 4: Global india chikungunya vaccine 2029 Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global india chikungunya vaccine 2029 Market Volume (K) By Region

Table 11: Global india chikungunya vaccine 2029 Market Share (%) By Region

Table 12: North America Market Volume (K) (2020-2024) By Country

Table 13: Europe Market Volume (K) (2020-2024) By Country

Table 14: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 15: South America Market Volume (K) (2020-2024) By Country

Table 16: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 17: Global india chikungunya vaccine 2029 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 18: Global india chikungunya vaccine 2029 Market: Profiled Players Head Office And Area Served

Table 19: Key Players Global india chikungunya vaccine 2029 Market:

Table 20: Mergers & Acquisitions, Expansion Plans

Table 21: Valneva SE Basic Information And Sales Area

Table 22: Valneva SE. Products Portfolio

Table 23: Emergent BioSolutions Inc. Basic Information And Sales Area

Table 24: Emergent BioSolutions Inc.. Products Portfolio

Table 25: Sanofi Basic Information And Sales Area

Table 26: Sanofi. Products Portfolio

Table 27: Bharat Biotech International Limited Basic Information And Sales Area

Table 28: Bharat Biotech International Limited. Products Portfolio

Table 29: Serum Institute of India Pvt. Ltd. Basic Information And Sales Area

Table 30: Serum Institute of India Pvt. Ltd.. Products Portfolio

Table 31: Biological E. Limited Basic Information And Sales Area

Table 32: Biological E. Limited. Products Portfolio

Table 33: Astellas Pharma Inc. Basic Information And Sales Area

Table 34: Astellas Pharma Inc.. Products Portfolio

Table 35: Ipsen S.A. Basic Information And Sales Area

Table 36: Ipsen S.A.. Products Portfolio

Table 37: Global india chikungunya vaccine 2029 Market Value (USD Million) By Region

Table 38: Global india chikungunya vaccine 2029 Market Share (%) By Region (2025-2032)

Table 39: North America Market Value (USD Million) (2025-2032) By Country

Table 40: Europe Market Value (USD Million) (2025-2032) By Country

Table 41: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 42: South America Market Value (USD Million) (2025-2032) By Country

Table 43: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 44: Global india chikungunya vaccine 2029 Market Volume (K) By Region

Table 45: Global india chikungunya vaccine 2029 Market Share (%) By Region (2025-2032)

Table 46: North America Market Volume (K) (2025-2032) By Country

Table 47: Europe Market Volume (K) (2025-2032) By Country

Table 48: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 49: South America Market Volume (K) (2025-2032) By Country

Table 50: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 51: Research Programs/Design For This Report

Table 52: Key Data Information From Secondary Sources

Table 53: Key Data Information From Primary Sources

FAQs

1. What is the projected india chikungunya vaccine 2029 market size?

Analysts value the india chikungunya vaccine 2029 market size at roughly USD 210 million, assuming successful late-stage trials, pan-India rollout, and moderate pricing; this figure triples 2025 estimates, reflecting strong public-sector procurement and rising traveller demand.

2. What growth forecast underpins the 2029 outlook?

Consensus projects a 42% CAGR from 2026-29, driven by post-approval surge orders, state-level immunisation drives, and WHO pre-qualification opening export channels; the future outlook sees volumes exceeding 40 million annual doses by 2029.

3. Which key drivers are fuelling adoption?

Recurrent monsoon outbreaks, traveller vaccination mandates, government subsidy schemes, and rising vector-control fatigue accelerate uptake; key drivers also include paediatric inclusion and single-dose regimens improving campaign economics.

4. What challenges could derail the market?

Cold-chain gaps in rural states, cold-storage cost pass-through, lingering vaccine hesitancy, and price-capping pressure pose challenges; concurrent dengue rollout may further strain immunisation budgets and health-worker bandwidth.

5. Which regional leaders will dominate sales?

Maharashtra, Karnataka, Tamil Nadu, Gujarat, and Kerala—states with high chikungunya seroprevalence, robust public-health budgets, and strong private hospital networks—are expected to account for 62% of 2029 doses.

6. Who are the top companies developing vaccines?

Bharat Biotech’s BBV87, Indian Immunologicals Ltd’s live-attenuated candidate, and Serum Institute’s viral-vector construct lead the pipeline; top companies also include Panacea Biotec and Zydus Lifesciences in early-phase trials.

7. What future opportunities exist beyond 2029?

Combination dengue-chikungunya shots, WHO pre-qualification for UN procurement, traveller clinics across APAC, and private preventive-health packages represent lucrative future opportunities for market entrants and existing players.

8. How is technology reshaping vaccine delivery?

Thermostable formulations, micro-arrayed skin patches, and blockchain-enabled cold-chain monitoring reduce spoilage and boost rural coverage; AI-driven outbreak prediction further refines dynamic stock deployment and campaign timing.

9. What does the regulatory landscape look like?

Subject Expert Committee fast-track review, waiver of local Phase-III if immunogenicity data align, and proposed inclusion in the National Technical Advisory Group on Immunisation schedule define the favourable regulatory landscape.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

india chikungunya vaccine 2029 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	1.03 billion
Growth rate	CAGR of 24.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Valneva SE; Emergent BioSolutions Inc.; Sanofi; Bharat Biotech International Limited; Serum Institute of India Pvt. Ltd.; Biological E. Limited; Astellas Pharma Inc.; Ipsen S.A.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options